Gue Su Chang on Muck Rack

Gue Su Chang

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gue Su

Contact Gue Su, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

|
By Ryan C Gimple, Kaleigh Roberts, Omar Butt, S. Peter Goedegebuure, Michael McLellan, Jasreet Hundal, Jian Yan, Jaye B. Navarro, Srestha Chattopadhyay, Alfredo Perales-Puchalt, Joann Peters, Jian L. Campian, Milan G. Chheda, Michael R. Chicoine, Albert Kim, Jon Willie, Gregory J. Zipfel, Joshua Dowling Verified, Christopher Miller, Obi L. Griffith, Malachi Griffith, William E. Gillanders, Katherine Miller, Elaine R. Mardis, Gavin P. Dunn, Tanner Johanns, Elizabeth A. R. Garfinkle, Renzo Perales-Linares, Alexandra J. Livingstone, Gue Su Chang, Sophia A. Paxton, Neil Cooch, Konstantina Stavroulaki, Sarah Rochestie, Beth Junker, Niranjan Y. Sardesai
| Nature Verified
Abstract Glioblastoma is a fatal disease with a median prognosis of 12–18 months. Recent studies have shown encouraging results using neoantigen-based vaccines to stimulate glioblastoma-directed immune responses, but overall immunogenicity has been low.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified